Mendus AB (IMMUN)

Currency in SEK
5.550
-0.050(-0.89%)
Closed·
IMMUN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.4305.620
52 wk Range
3.86010.980
Key Statistics
Prev. Close
5.6
Open
5.5
Day's Range
5.43-5.62
52 wk Range
3.86-10.98
Volume
20.89K
Average Volume (3m)
34.05K
1-Year Change
13.0346%
Book Value / Share
9.21
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMMUN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
16.000
Upside
+188.29%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 16.000
(+188.29% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
May 08, 2026
EPS / Forecast
-0.34 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

IMMUN Income Statement

Compare IMMUN to Peers and Sector

Metrics to compare
IMMUN
Peers
Sector
Relationship
P/E Ratio
−3.3x−0.5x−0.5x
PEG Ratio
−0.140.000.00
Price/Book
0.6x2.7x2.6x
Price / LTM Sales
-0.0x3.1x
Upside (Analyst Target)
188.3%0.0%52.5%
Fair Value Upside
Unlock47.6%6.0%Unlock

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company’s lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2. It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
331.03K0.54%1.85M
Other Institutional Investors
47.05M76.70%263.50M
Public Companies & Retail Investors
13.96M22.76%78.20M
Total
61.35M100.00%343.55M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Van Herk Investments B.V.36.45%22,360,176125,217
Flerie AB (publ)23.06%14,145,24279,213

FAQ

What Is the Mendus AB (IMMUN) Stock Price Today?

The Mendus AB stock price today is 5.550 SEK.

What Stock Exchange Does Mendus AB Trade On?

Mendus AB is listed and trades on the Stockholm Stock Exchange.

What Is the Stock Symbol for Mendus AB?

The stock symbol for Mendus AB is "IMMUN."

What Is the Mendus AB Market Cap?

As of today, Mendus AB market cap is 340.490M SEK.

What Is Mendus AB's Earnings Per Share (TTM)?

The Mendus AB EPS (TTM) is -1.882.

When Is the Next Mendus AB Earnings Date?

Mendus AB will release its next earnings report on Aug 20, 2026.

From a Technical Analysis Perspective, Is IMMUN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Mendus AB Stock Split?

Mendus AB has split 4 times.

How Many Employees Does Mendus AB Have?

Mendus AB has 27 employees.

What is the current trading status of Mendus AB (IMMUN)?

As of May 26, 2026, Mendus AB (IMMUN) is trading at a price of 5.550 SEK, with a previous close of 5.600 SEK. The stock has fluctuated within a day range of 5.430 SEK to 5.620 SEK, while its 52-week range spans from 3.860 SEK to 10.980 SEK.

What Is Mendus AB (IMMUN) Price Target According to Analysts?

The average 12-month price target for Mendus AB is 16.000 SEK, with a high estimate of 16 SEK and a low estimate of 16 SEK. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +188.29% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.